Overview

Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled

Status:
Completed
Trial end date:
2018-03-23
Target enrollment:
Participant gender:
Summary
To examine variation rate of Non-HDL with KI1106 comparison Atorvastatin monotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Kuhnil Pharmaceutical Co., Ltd.
Treatments:
Atorvastatin
Atorvastatin Calcium
Calcium
Calcium, Dietary